DEPARTMENT OF HEALTH & HUMAN SERVICES

m3133n

Food and Drug Administration
Detroit District
1560 East Jefferson Avenue
Detroit, MI 48207-3179
Telephone: 313-226-6260

CERTIFIED MAIL

RETURN RECEIPT REQUESTED

WARNING LETTER
2000-DT-01

October 7, 1999

Mr. Leonard L. Mazur
President
Genesis Pharmaceutical, Inc.
44 Whippany Road
Morristown, NJ 07960

Dear Mr. Mazur:

An inspection of your subsidiary firm, C & M Pharmacal, Inc. Hazel Park, MI, was conducted on June 3 – July 14, 1999 by Investigators Leslie A. Paul and Renee L. Rice. At the conclusion of the inspection a FORM FDA-483, list of Inspectional Observations, was issued to Mr. Elliott A. Milstein, Executive Vice President.

The drug products sold by your firm are adulterated within the meaning of Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (the Act) based on inspectional evidence which revealed serious deviations from Current Good Manufacturing Practices for Finished Pharmaceuticals, Part 211 (21CFR211), including the following:

1. There is no validation to support the suitability of the analytical test methods under actual conditions for use.

2. Review of the process validation for drugs revealed:
   a. no written validation protocols.
   b. no upper and lower processing limits.
   c. no evaluation of holding time (maximum 30 days) of compounded material in drums prior to filling.
   d. no validation of packaging in final containers.
   e. no installation, operational, and process qualification of the tube filler that was installed in 1997.

3. Validation has not been performed for the cleaning process for all equipment used in manufacturing drug products.

We wish to point out that many of the observations were similar to those listed on an earlier FDA-483 issued to Mr. Milstein at the conclusion of the August 27 – September 15, 1998 inspection. That FDA-483 resulted in a written response that indicated the validation issues were being addressed. The current inspection showed that after nine months, almost no progress had been made.

Mr. Milstein has responded in writing to these and other observations that were outlined in detail on the latest FDA-483, in letters dated August 3, 1999 and September 7, 1999. This will acknowledge receipt of his two letters, and the accompanying documents which describe actions that have been planned or implemented.

The letters fail to indicate the current manufacturing status of the drug products prior to correction of all the violative conditions.

We have reviewed the Master Validation Plan dated August 1999, included with the September 7, 1999 letter. The plan, when implemented, appears to include all the necessary factors for a prospective validation of the analytical test methods and the process and cleaning procedures.

Please provide this office with the initial protocols, as they become available, that you plan to use in the analytical methods validation work, and subsequently, protocols for the equipment qualification, production process, and cleaning validations.

The September 7, 1999 letter indicates that initiation of the Master Validation Plan may take three months, before specific product process validations can begin. Then a 24 – 30 month time frame is expected for completion of all the process validation studies.

The time frames described in the letter are not acceptable if production of these drug products continues in the interim.

The above is not intended to be an all-inclusive list of deviations which may exist at your firm. It is your responsibility to ensure that your firm is in full compliance with the Act and regulations promulgated thereunder. Other Federal agencies are advised of the issuance of all Warning Letters about drugs so that they may take this information into account when considering the award of contracts.

We request that you take prompt action to correct these deviations. Failure to make prompt corrections may result in regulatory action without further notice, such as seizure and/or injunction.

Please notify this office in writing, within fifteen (15) working days of your receipt of this letter, of the specific steps you have taken to correct the noted deviations and to prevent their recurrence. If corrective action cannot be completed within 15 working days, please state the reason for the delay, and the time in which the corrections will be completed.

Your response should be directed to this office to the attention of Mr. Melvin O. Robinson, Compliance Officer. (313) 226-6260 Extension 128.

Sincerely yours,

John P. Dempster

for Raymond V. Mlecko
District Director
Detroit District

Cc: Mr. Elliott A. Milstein
Executive Vice President
C & M Pharmacal, Inc.
1721 Maplelane Avenue
Hazel Park, MI 48030